Compare Allegion PLC (ALLE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Vertex Pharmaceuticals Incorporated trades at $489.74 (market cap $123.19B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.5× Allegion PLC's market cap, and Allegion PLC pays a 1.55% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ALLE | VRTX | |
|---|---|---|
Market Cap | $11.74B | $123.19B |
Sector | Industrials | Health |
52-Week High | $179.77 | $529.59 |
52-Week Low | $125.65 | $366.54 |
Enterprise Value | $13.46B | $117.93B |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
Vertex Pharmaceuticals (VRTX) trades at $485.39, down 2.24% today but maintains a bullish technical trend with strong support at $486. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though margins dipped slightly. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expanding its endocrinology portfolio with potential $5B peak sales. Analyst consensus remains strongly bullish with an 83.9% buy rating and $526.50 price target.
Outlook is positive driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. The stock offers upside to consensus targets but faces volatility near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
